$RPRX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Royalty Pharma plc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Royalty Pharma plc. Get notifications about new insider transactions in Royalty Pharma plc for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 29 2021 | RPRX | Royalty Pharma plc | LOVE TED W | Director | Grant | A | 0.00 | 5,726 | 0 | 22,866 | 17.1 K to 22.9 K (+33.41 %) |
Jun 29 2021 | RPRX | Royalty Pharma plc | LOVE TED W | Director | Grant | A | 0.00 | 5,726 | 0 | 22,866 | 17.1 K to 22.9 K (+33.41 %) |
Jun 29 2021 | RPRX | Royalty Pharma plc | DESOUZA ERROL B | Director | Grant | A | 0.00 | 5,726 | 0 | 50,370 | 44.6 K to 50.4 K (+12.83 %) |
Jun 29 2021 | RPRX | Royalty Pharma plc | DESOUZA ERROL B | Director | Grant | A | 0.00 | 5,726 | 0 | 50,370 | 44.6 K to 50.4 K (+12.83 %) |
Jun 29 2021 | RPRX | Royalty Pharma plc | Fernandez Henry A | Director | Grant | A | 0.00 | 5,726 | 0 | 15,115 | 9.4 K to 15.1 K (+60.99 %) |
Jun 29 2021 | RPRX | Royalty Pharma plc | Fernandez Henry A | Director | Grant | A | 0.00 | 5,726 | 0 | 15,115 | 9.4 K to 15.1 K (+60.99 %) |
Jun 04 2021 | RPRX | Royalty Pharma plc | Urist Marshall | EVP & Co-Head Resea ... | Sell | S | 41.52 | 14,566 | 604,850 | 33,134 | 47.7 K to 33.1 K (-30.54 %) |
Jun 04 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 42.13 | 50,000 | 2,106,385 | 1,050,000 | 1.1 M to 1.1 M (-4.55 %) |
Jun 04 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 42.09 | 12,500 | 526,128 | 713,360 | 725.9 K to 713.4 K (-1.72 %) |
May 11 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Option Exercise | C | 0.00 | 100,000 | 0 | 22,945 | |
May 11 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Buy | C | 0.00 | 1,000,000 | 0 | 1,000,000 | 0 to 1000 K |
May 11 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Option Exercise | C | 0.00 | 30,000 | 0 | 264,027 | |
May 11 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Option Exercise | C | 0.00 | 90,000 | 0 | 172,680 | |
May 11 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Option Exercise | C | 0.00 | 67,586 | 0 | 0 | |
May 11 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Buy | C | 0.00 | 300,000 | 0 | 300,000 | 0 to 300 K |
May 11 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Buy | C | 0.00 | 900,000 | 0 | 1,100,000 | 200 K to 1.1 M (+450.00 %) |
May 11 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Buy | C | 0.00 | 675,860 | 0 | 725,860 | 50 K to 725.9 K (+1,351.72 %) |
May 11 2021 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | C | 0.00 | 128,459 | 0 | 0 | |
May 11 2021 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | C | 0.00 | 104,041 | 0 | 0 | |
May 11 2021 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Buy | C | 0.00 | 1,284,590 | 0 | 1,284,590 | 0 to 1.3 M |
May 11 2021 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Buy | C | 0.00 | 1,040,410 | 0 | 1,040,410 | 0 to 1 M |
May 11 2021 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Option Exercise | C | 0.00 | 235,519 | 0 | 0 | |
May 11 2021 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Option Exercise | C | 0.00 | 67,976 | 0 | 541,751 | |
May 11 2021 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Buy | C | 0.00 | 2,355,190 | 0 | 2,355,190 | 0 to 2.4 M |
May 11 2021 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Buy | C | 0.00 | 679,760 | 0 | 679,760 | 0 to 679.8 K |
May 11 2021 | RPRX | Royalty Pharma plc | Urist Marshall | EVP & Co-Head Resea ... | Option Exercise | C | 0.00 | 4,970 | 0 | 142,594 | |
May 11 2021 | RPRX | Royalty Pharma plc | Urist Marshall | EVP & Co-Head Resea ... | Buy | C | 0.00 | 49,700 | 0 | 49,700 | 0 to 49.7 K |
May 11 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | C | 0.00 | 132,080 | 0 | 486,398 | |
May 11 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Buy | C | 0.00 | 1,320,800 | 0 | 1,520,800 | 200 K to 1.5 M (+660.40 %) |
Apr 16 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 42.14 | 55,898 | 2,355,486 | 200,000 | 255.9 K to 200 K (-21.84 %) |
Apr 16 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 42.12 | 13,924 | 586,434 | 50,000 | 63.9 K to 50 K (-21.78 %) |
Apr 16 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Sell | S | 42.10 | 55,714 | 2,345,593 | 200,000 | 255.7 K to 200 K (-21.79 %) |
Apr 14 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 42.32 | 360 | 15,235 | 255,898 | 256.3 K to 255.9 K (-0.14 %) |
Apr 14 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 42.32 | 89 | 3,766 | 63,924 | 64 K to 63.9 K (-0.14 %) |
Apr 14 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Sell | S | 42.32 | 359 | 15,193 | 255,714 | 256.1 K to 255.7 K (-0.14 %) |
Apr 02 2021 | RPRX | Royalty Pharma plc | Bassler Bonnie L | Director | Grant | A | 45.90 | 816 | 37,458 | 15,183 | 14.4 K to 15.2 K (+5.68 %) |
Apr 02 2021 | RPRX | Royalty Pharma plc | Fernandez Henry A | Director | Grant | A | 45.90 | 816 | 37,458 | 9,529 | 8.7 K to 9.5 K (+9.37 %) |
Mar 25 2021 | RPRX | Royalty Pharma plc | Hite Christopher | EVP & Vice Chairman | Option Exercise | S | 0.00 | 31,959 | 0 | 30,541 | |
Mar 24 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Sell | S | 46.32 | 43,927 | 2,034,519 | 256,073 | 300 K to 256.1 K (-14.64 %) |
Mar 24 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 47.04 | 100 | 4,704 | 256,258 | 256.4 K to 256.3 K (-0.04 %) |
Mar 24 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 46.32 | 43,642 | 2,021,436 | 256,358 | 300 K to 256.4 K (-14.55 %) |
Mar 24 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 46.34 | 10,987 | 509,086 | 64,013 | 75 K to 64 K (-14.65 %) |
Mar 05 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Sell | S | 46.83 | 1,456 | 68,184 | 200,000 | 201.5 K to 200 K (-0.72 %) |
Mar 05 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Sell | S | 45.86 | 11,001 | 504,459 | 201,456 | 212.5 K to 201.5 K (-5.18 %) |
Mar 05 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Sell | S | 45.09 | 57,723 | 2,602,465 | 212,457 | 270.2 K to 212.5 K (-21.36 %) |
Mar 05 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Sell | S | 43.71 | 29,820 | 1,303,343 | 270,180 | 300 K to 270.2 K (-9.94 %) |
Mar 04 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 47.85 | 3,510 | 167,948 | 300,000 | 303.5 K to 300 K (-1.16 %) |
Mar 04 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 46.89 | 96,490 | 4,524,368 | 303,510 | 400 K to 303.5 K (-24.12 %) |
Mar 04 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 47.84 | 2,625 | 125,575 | 75,000 | 77.6 K to 75 K (-3.38 %) |
Mar 04 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Sell | S | 46.89 | 22,375 | 1,049,258 | 77,625 | 100 K to 77.6 K (-22.37 %) |
Mar 04 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Sell | S | 47.84 | 3,510 | 167,925 | 300,000 | 303.5 K to 300 K (-1.16 %) |
Mar 04 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Sell | S | 46.89 | 96,490 | 4,524,233 | 303,510 | 400 K to 303.5 K (-24.12 %) |
Mar 04 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Sell | S | 47.88 | 5,022 | 240,429 | 300,000 | 305 K to 300 K (-1.65 %) |
Mar 04 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Sell | S | 46.89 | 94,978 | 4,453,661 | 305,022 | 400 K to 305 K (-23.74 %) |
Feb 26 2021 | RPRX | Royalty Pharma plc | Fernandez Henry A | Director | Buy | P | 46.83 | 25,700 | 1,203,480 | 25,700 | 0 to 25.7 K |
Feb 26 2021 | RPRX | Royalty Pharma plc | FORD WILLIAM E | Director | Option Exercise | C | 0.00 | 58,187 | 0 | 0 | |
Feb 26 2021 | RPRX | Royalty Pharma plc | FORD WILLIAM E | Director | Sell | J | 0.00 | 42,101 | 0 | 539,769 | 581.9 K to 539.8 K (-7.24 %) |
Feb 26 2021 | RPRX | Royalty Pharma plc | FORD WILLIAM E | Director | Buy | C | 0.00 | 581,870 | 0 | 581,870 | 0 to 581.9 K |
Jan 05 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Option Exercise | C | 0.00 | 30,023 | 0 | 376,468 | |
Jan 05 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Option Exercise | C | 0.00 | 9,977 | 0 | 778 | |
Jan 05 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Buy | C | 0.00 | 300,230 | 0 | 400,000 | 99.8 K to 400 K (+300.92 %) |
Jan 05 2021 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Buy | C | 0.00 | 99,770 | 0 | 99,770 | 0 to 99.8 K |
Jan 05 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | C | 0.00 | 12,990 | 0 | 618,478 | |
Jan 05 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | C | 0.00 | 27,010 | 0 | 2,107 | |
Jan 05 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Buy | C | 0.00 | 129,900 | 0 | 400,000 | 270.1 K to 400 K (+48.09 %) |
Jan 05 2021 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Buy | C | 0.00 | 270,100 | 0 | 270,100 | 0 to 270.1 K |
Jan 05 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Option Exercise | C | 0.00 | 40,000 | 0 | 556,707 | |
Jan 05 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Option Exercise | C | 0.00 | 10,000 | 0 | 73,638 | |
Jan 05 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Buy | C | 0.00 | 400,000 | 0 | 400,000 | 0 to 400 K |
Jan 05 2021 | RPRX | Royalty Pharma plc | Lloyd George W. | EVP, Investments & ... | Buy | C | 0.00 | 100,000 | 0 | 100,000 | 0 to 100 K |
Jan 04 2021 | RPRX | Royalty Pharma plc | Fernandez Henry A | Director | Grant | A | 45.69 | 820 | 37,464 | 8,713 | 7.9 K to 8.7 K (+10.39 %) |
Jan 04 2021 | RPRX | Royalty Pharma plc | Bassler Bonnie L | Director | Grant | A | 45.69 | 820 | 37,464 | 14,367 | 13.5 K to 14.4 K (+6.05 %) |
Dec 18 2020 | RPRX | Royalty Pharma plc | ADAGE CAPITAL PARTNERS GP, L.L ... | 10% Owner | Sell | S | 44.02 | 101,050 | 4,448,221 | 38,714,280 | 38.8 M to 38.7 M (-0.26 %) |
Dec 18 2020 | RPRX | Royalty Pharma plc | ADAGE CAPITAL PARTNERS GP, L.L ... | 10% Owner | Sell | S | 43.92 | 7,200,000 | 316,224,000 | 38,815,330 | 46 M to 38.8 M (-15.65 %) |
Oct 22 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Option Exercise | C | 0.00 | 46,320 | 0 | 191,681 | |
Oct 22 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Option Exercise | C | 0.00 | 46,320 | 0 | 191,681 | |
Oct 22 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Sell | S | 42.00 | 463,200 | 19,454,400 | 0 | 463.2 K to 0 (-100.00 %) |
Oct 22 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Sell | S | 42.00 | 463,200 | 19,454,400 | 0 | 463.2 K to 0 (-100.00 %) |
Oct 22 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Buy | C | 0.00 | 463,200 | 0 | 463,200 | 0 to 463.2 K |
Oct 22 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Buy | C | 0.00 | 463,200 | 0 | 463,200 | 0 to 463.2 K |
Oct 02 2020 | RPRX | Royalty Pharma plc | Fernandez Henry A | Director | Grant | A | 41.17 | 613 | 25,240 | 7,893 | 7.3 K to 7.9 K (+8.42 %) |
Oct 02 2020 | RPRX | Royalty Pharma plc | Engelbert Catherine M. | Director | Grant | A | 41.17 | 910 | 37,468 | 13,410 | 12.5 K to 13.4 K (+7.28 %) |
Oct 02 2020 | RPRX | Royalty Pharma plc | Bassler Bonnie L | Director | Grant | A | 41.17 | 910 | 37,468 | 13,547 | 12.6 K to 13.5 K (+7.20 %) |
Sep 23 2020 | RPRX | Royalty Pharma plc | Norden Gregory | Director | Option Exercise | A | 0.00 | 15,594 | 0 | 15,594 | |
Sep 23 2020 | RPRX | Royalty Pharma plc | Norden Gregory | Director | Grant | A | 0.00 | 8,929 | 0 | 44,644 | 35.7 K to 44.6 K (+25.00 %) |
Sep 23 2020 | RPRX | Royalty Pharma plc | Engelbert Catherine M. | Director | Grant | A | 0.00 | 12,500 | 0 | 12,500 | 0 to 12.5 K |
Sep 23 2020 | RPRX | Royalty Pharma plc | DESOUZA ERROL B | Director | Option Exercise | A | 0.00 | 53,915 | 0 | 53,915 | |
Sep 23 2020 | RPRX | Royalty Pharma plc | DESOUZA ERROL B | Director | Grant | A | 0.00 | 8,929 | 0 | 44,644 | 35.7 K to 44.6 K (+25.00 %) |
Sep 23 2020 | RPRX | Royalty Pharma plc | Bassler Bonnie L | Director | Grant | A | 48.00 | 137 | 6,576 | 12,637 | 12.5 K to 12.6 K (+1.10 %) |
Sep 23 2020 | RPRX | Royalty Pharma plc | Bassler Bonnie L | Director | Grant | A | 0.00 | 12,500 | 0 | 12,500 | 0 to 12.5 K |
Sep 23 2020 | RPRX | Royalty Pharma plc | Norden Gregory | Director | Option Exercise | A | 0.00 | 15,594 | 0 | 15,594 | |
Sep 23 2020 | RPRX | Royalty Pharma plc | Norden Gregory | Director | Grant | A | 0.00 | 8,929 | 0 | 44,644 | 35.7 K to 44.6 K (+25.00 %) |
Sep 23 2020 | RPRX | Royalty Pharma plc | Engelbert Catherine M. | Director | Grant | A | 0.00 | 12,500 | 0 | 12,500 | 0 to 12.5 K |
Sep 23 2020 | RPRX | Royalty Pharma plc | DESOUZA ERROL B | Director | Option Exercise | A | 0.00 | 53,915 | 0 | 53,915 | |
Sep 23 2020 | RPRX | Royalty Pharma plc | DESOUZA ERROL B | Director | Grant | A | 0.00 | 8,929 | 0 | 44,644 | 35.7 K to 44.6 K (+25.00 %) |
Sep 23 2020 | RPRX | Royalty Pharma plc | Bassler Bonnie L | Director | Grant | A | 48.00 | 137 | 6,576 | 12,637 | 12.5 K to 12.6 K (+1.10 %) |
Sep 23 2020 | RPRX | Royalty Pharma plc | Bassler Bonnie L | Director | Grant | A | 0.00 | 12,500 | 0 | 12,500 | 0 to 12.5 K |
Aug 17 2020 | RPRX | Royalty Pharma plc | Fernandez Henry A | Director | Grant | A | 0.00 | 7,280 | 0 | 7,280 | 0 to 7.3 K |
Aug 17 2020 | RPRX | Royalty Pharma plc | LOVE TED W | Director | Grant | A | 0.00 | 7,280 | 0 | 17,280 | 10 K to 17.3 K (+72.80 %) |
Jun 23 2020 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Option Exercise | C | 0.00 | 2,327 | 0 | 181 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Option Exercise | A | 0.00 | 48,000 | 0 | 48,000 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Option Exercise | A | 0.00 | 305,000 | 0 | 305,000 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Option Exercise | A | 0.00 | 2,508 | 0 | 2,508 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Option Exercise | A | 0.00 | 406,491 | 0 | 406,491 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Option Exercise | A | 0.00 | 10,755 | 0 | 10,755 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Buy | C | 0.00 | 23,270 | 0 | 23,270 | 0 to 23.3 K |
Jun 23 2020 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Buy | P | 28.00 | 1,450 | 40,600 | 1,450 | 0 to 1.5 K |
Jun 23 2020 | RPRX | Royalty Pharma plc | Coyne Terrance P. | EVP & CFO | Buy | P | 28.00 | 1,500 | 42,000 | 1,500 | 0 to 1.5 K |
Jun 23 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Option Exercise | A | 0.00 | 119,982 | 0 | 119,982 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Option Exercise | A | 0.00 | 494,485 | 0 | 494,485 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Option Exercise | A | 0.00 | 253,889 | 0 | 253,889 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Option Exercise | A | 0.00 | 435,267 | 0 | 435,267 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Option Exercise | A | 0.00 | 238,001 | 0 | 238,001 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | RIGGS RORY B | Director | Buy | P | 28.00 | 15,000 | 420,000 | 15,000 | 0 to 15 K |
Jun 23 2020 | RPRX | Royalty Pharma plc | Hite Christopher | EVP & Vice Chairman | Option Exercise | A | 0.00 | 116,100 | 0 | 116,100 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | Hite Christopher | EVP & Vice Chairman | Option Exercise | A | 0.00 | 62,500 | 0 | 62,500 | |
Jun 23 2020 | RPRX | Royalty Pharma plc | Hite Christopher | EVP & Vice Chairman | Buy | P | 28.00 | 70,000 | 1,960,000 | 70,000 | 0 to 70 K |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | C | 0.00 | 2,503 | 0 | 195 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | C | 0.00 | 2,503 | 0 | 195 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | A | 0.00 | 200,000 | 0 | 200,000 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | A | 0.00 | 200,000 | 0 | 200,000 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | A | 0.00 | 2,698 | 0 | 2,698 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | A | 0.00 | 2,698 | 0 | 2,698 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | A | 0.00 | 631,468 | 0 | 631,468 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | A | 0.00 | 631,468 | 0 | 631,468 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | A | 0.00 | 29,117 | 0 | 29,117 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Option Exercise | A | 0.00 | 29,117 | 0 | 29,117 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Buy | C | 0.00 | 25,030 | 0 | 25,030 | 0 to 25 K |
Jun 22 2020 | RPRX | Royalty Pharma plc | Reddoch James F. | EVP, Research & Inv ... | Buy | C | 0.00 | 25,030 | 0 | 25,030 | 0 to 25 K |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | C | 0.00 | 11,850 | 0 | 924 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | C | 0.00 | 11,850 | 0 | 924 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | C | 0.00 | 12,331 | 0 | 962 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | C | 0.00 | 12,331 | 0 | 962 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 1,677,574 | 0 | 1,677,574 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 1,677,574 | 0 | 1,677,574 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 12,774 | 0 | 12,774 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 12,774 | 0 | 12,774 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 13,293 | 0 | 13,293 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 13,293 | 0 | 13,293 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 4,868,033 | 0 | 4,868,033 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 4,868,033 | 0 | 4,868,033 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 138,479 | 0 | 138,479 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 138,479 | 0 | 138,479 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 112,156 | 0 | 112,156 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 112,156 | 0 | 112,156 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 942,738 | 0 | 942,738 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Option Exercise | A | 0.00 | 942,738 | 0 | 942,738 | |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Buy | C | 0.00 | 118,500 | 0 | 118,500 | 0 to 118.5 K |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Buy | C | 0.00 | 118,500 | 0 | 118,500 | 0 to 118.5 K |
Jun 22 2020 | RPRX | Royalty Pharma plc | Legorreta Pablo G. | CEO, Chairman of th ... | Buy | C | 0.00 | 123,310 | 0 | 123,310 | 0 to 123.3 K |